samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > a new age for biotechnology - 18th to 19th june 2001, london
PUBLICATIONS
European Biopharmaceutical Review

A New Age for Biotechnology - 18th to 19th June 2001, London

The financing and business environment for biotechnology in Europe was very much the theme of this two-day conference run by Marcus Evans in London in June. Following introductory comments by the first day's Chairman, Nick Woolf, Biotech Analyst at ABN Amro, the conference kicked off with an overview of the latest developments from Shawn Cross, Vice President Healthcare Investment Banking at Deutsche Bank. Shaun described the peaks and troughs of biotech valuation cycles over the last four to five years and the pattern of IPOs in the sector before the peak of 2000. All agreed that 2000 had been a stellar year and no-one should expect a repeat any time soon. However, activity levels and investor interest were presented as having stabilised following the slump at the beginning of this year, and private equity firms were described as still favourably disposed towards biotech investment. Finally, PIPEs (private investment in public equity) were presented as having come of age in the current environment, as a popular financing tool for biotechs to consider. The advantages listed were their speed and lower costs as a means to raise funds without the time out on the road. The disadvantages were listed to include the dilution effect for the existing shareholders and the discounts at which private buyers could access the shares.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott, Editor of EBR
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases

MyMD Pharmaceuticals Inc., a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled “Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.”
More info >>

White Papers

Conveying Medical Guidance in Clinical Trials – A Survey

Europital Medical Consultancy

With the incremental demand for proactive safety surveillance throughout the conduct of clinical trials, the role of Medical Management is at the fore in ensuring the safety and wellbeing of the participants. The complex responsibilities of a Medical Monitor (MM) starts from the design and development phase, through to study close out. Understanding the principle behind the protocol and the prospective medical solution the study would deliver forms the bloodline for the MM role. Often, the MM is the face of contact for both the site personnel and the study team members with regard to medical, safety and scientific issues within the project. When it comes to medical guidance, the communication channel used to deliver solutions contributes to a large extent in effectively managing decisive situations. Our previous study on acquiring medical guidance from an operations team perspective revealed that e-mails were the most used communication method (see the article, 'Talking Points', in ICT November 2014). In our efforts to further strengthen the mode of medical guidance delivery, we designed a survey to study the existing trend and constraints in this communication chain management, as outlined here.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement